Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.54 |
| ▸ | ALPL | P05186 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527555 | 0.95 | HCAR2 (0.53) | HCAR2HCAR3ALPLCA12CA9 | |
| Hydrochloric Acid SCHEMBL27449787 | 0.93 | HCAR2 (0.51) | HCAR2HCAR3ALPLCA12CA9 | |
| SCHEMBL1092 | 0.88 | HCAR3 (0.54) | HCAR2HCAR3ALPLCA12CA9 | |
| Hydrochloric Acid SCHEMBL31467460 | 0.86 | HCAR3 (0.53) | HCAR2HCAR3ALPLCA12CA9 | |
| SCHEMBL16763221 | 0.84 | HCAR3 (0.50) | HCAR2HCAR3ALPLCA12CA9 | |
| SCHEMBL6111559 | 0.81 | HCAR3 (0.43) | HCAR2HCAR3ALPLCA12CA9 | |
| SCHEMBL1431995 | 0.80 | ALPL (0.54) | HCAR2HCAR3ALPLCA12CA9 | |
| SCHEMBL4057741 | 0.80 | HCAR2 (0.44) | HCAR2HCAR3ALPLPPARA | |
| SCHEMBL6109364 | 0.79 | HCAR3 (0.44) | HCAR2HCAR3ALPLCA12CA9 | |
| SCHEMBL11666797 | 0.78 | HCAR2 (0.48) | HCAR2HCAR3PPARAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | JOHN HOPKINS UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-6569862-B1 | Adminstering xanthine oxidase inhibitor such as allopurinol | JOHNS HOPKINS UNIVERSITY | 2003-05-27 | — | — | US | disclosed |
| EP-1044002-A4 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | UNIV JOHNS HOPKINS (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6191136-B1 | ADMINISTERING XANTHINE OXIDASE INHIBITOR | JOHNS HOPKINS UNIVERSITY | 2001-02-20 | — | — | US | disclosed |
| EP-1044002-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999024038-A1 | METHODS FOR TREATMENT OF DISORDERS OF CARDIAC CONTRACTILITY | JOHNS HOPKINS UNIVERSITY (US) | 1999-05-20 | — | — | WO | disclosed |
| US-4495195-A | ANTI-GOUT, ANTI-GOUTY ARTHRITIS AGENTS | ELI LILLY AND COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0112623-A2 | 3-Aryl-5-pyrazole-carboxylic-acid derivatives, their preparation and pharmaceutical compositions | ELI LILLY AND COMPANY (US) | 1984-07-04 | — | — | EP | disclosed |
| EP-0112623-A2 | 3-Aryl-5-pyrazole-carboxylic-acid derivatives, their preparation and pharmaceutical compositions | ELI LILLY AND COMPANY (US) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186998-A1 | Methods for treatment of disorders of cardiac contractility | TNNI3, TNNT2, RYR2 | HCAR2 362/4885HCAR3 416/4885ALPL 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.